Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?

Circulation. 2015 Aug 4;132(5):433-40. doi: 10.1161/CIRCULATIONAHA.115.014026.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides
  • Animals
  • Anticholesteremic Agents / therapeutic use*
  • Benzodiazepines / therapeutic use
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / physiopathology
  • Cardiovascular Diseases / prevention & control*
  • Cholesterol Ester Transfer Proteins / antagonists & inhibitors*
  • Cholesterol Ester Transfer Proteins / deficiency
  • Cholesterol Ester Transfer Proteins / genetics
  • Cholesterol Ester Transfer Proteins / physiology*
  • Disease Models, Animal
  • Esters
  • Humans
  • Lipid Metabolism, Inborn Errors / genetics
  • Lipid Metabolism, Inborn Errors / physiopathology
  • Mice
  • Oxazolidinones / therapeutic use
  • Quinolines / therapeutic use
  • Rabbits
  • Risk Factors
  • Sulfhydryl Compounds / therapeutic use
  • Treatment Outcome

Substances

  • Amides
  • Anticholesteremic Agents
  • CETP protein, human
  • Cholesterol Ester Transfer Proteins
  • Esters
  • Oxazolidinones
  • Quinolines
  • Sulfhydryl Compounds
  • Benzodiazepines
  • dalcetrapib
  • torcetrapib
  • evacetrapib
  • anacetrapib

Supplementary concepts

  • Cholesteryl Ester Transfer Protein Deficiency